Health & Care INNOVATION
Disruptive opto-biological platform technology for personalized targeted Point-of-Care invivo cancer biomarker diagnosis
SHARE:
Market Maturity: Market Ready
These are innovations that are outperforming in innovation management and innovation readiness, and are considered to be "Ready for the market". Learn more
Market Creation Potential
This innovation was assessed by the JRC’s Market Creation Potential indicator framework as having a High” level of Market Creation Potential. Only innovations that are showing multiple signals of market creation potential are assigned a value under this indicator system. Learn more
Women-led innovation
A woman had a leadership role in developing this innovation in at least one of the Key Innovator organisations listed below.
Go to Market needs
Needs that, if addressed, can increase the chances this innovation gets to (or closer to) the market incude:
  • Secure capital
Location of Key Innovators developing this innovation
Key Innovators
SDS OPTIC SPOLKA AKCYJNA
LUBLIN, PL
Small or Medium Enterprise
The EU-funded Research Project
This innovation was developed under the Horizon 2020 project SDS-OmiProbe with an end date of 31/07/2021
Description of Project SDS-OmiProbe
According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women, and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease. Current diagnosis methods of cancers fail to deliver objective results. Diagnosis require extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which are subject to significant levels of discordance. SDS Optic presents a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS-OmiProbe detects presence and measures concentration levels of the HER2+ cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs. There is compelling evidence that our novel SDS-OmiProbe is addressing a rapid growth trend in a high volume market. Based on Transparency Market Research Report the OmiProbe target market of HER2- biomarker tests is projected to be worth $4.6 billion, with 7.5 million HER2 marker tests performed annually worldwide. In order to close the striking gap in the landscape of currently available cancer diagnostic and targeted therapy tools, and to realize the significant global business opportunity the objective of this project is optimization of the SDS-OmiProbe device, followed by realization of independent clinical trials and dissemination of the results.

Innnovation Radar's analysis of this innovation is based on data collected on 21/10/2019.